Femoropopliteal Occlusive Disease

37.1Definition and clinical presentation

Femoropopliteal occlusive disease presents either as functionally limiting claudication or chronic limb-threatening ischemia (CLTI). Claudication is characterized by exertional limitation, and revascularization is indicated only after an inadequate response to medical therapy and structured exercise ACC/AHA 2024. CLTI is a severe disease state characterized by rest pain or tissue loss, where intervention is indicated to achieve limb salvage rather than simply reproduce exertional symptom relief.

37.2Evaluation and risk stratification

Evaluation of femoropopliteal disease requires objective documentation of peripheral artery disease and baseline limb threat staging. A resting ankle-brachial index of 0.90 or lower is diagnostic of peripheral artery disease; an index above 1.40 indicates noncompressible, medially calcified vessels, and toe pressure or transcutaneous oximetry is substituted ACC/AHA 2024. Hemodynamic confirmation of chronic limb-threatening ischemia in a patient with ischemic rest pain typically requires an ankle pressure below 50 mmHg or a toe pressure below 30 mmHg GVG 2019. For CLTI, management requires integrating patient risk, limb severity, and anatomic complexity, formalized as the PLAN framework. The WIfI classification system grades limb threat. The GLASS system stages the target arterial path for infrainguinal disease and requires angiographic assessment; it is not inferred from clinical symptoms alone.

Preprocedural conduit mapping is mandatory for CLTI planning. The availability of an adequate single-segment great saphenous vein fundamentally alters expected surgical outcomes and revascularization strategy BEST-CLI · 2022.

37.3Management thresholds and procedural selection

Medical therapy and supervised exercise are first-line management for claudication. Supervised exercise therapy is walking to moderate-to-maximum claudication in sessions of 30 to 45 minutes, at least three times weekly, for a minimum of 12 weeks ACC/AHA 2024. Best medical therapy comprises antiplatelet monotherapy, a high-intensity statin, and smoking cessation; cilostazol 100 mg twice daily improves walking distance in claudication but is contraindicated in heart failure of any severity, and after revascularization low-dose rivaroxaban 2.5 mg twice daily plus aspirin reduces adverse limb and cardiovascular events (VOYAGER PAD). Revascularization is reserved for functionally limiting symptoms refractory to conservative care.

Treatment modality in femoropopliteal disease depends on the indication, lesion length, and available venous conduit. Shorter femoropopliteal stenoses or occlusions favor an endovascular-first approach, while longer lesions achieve better long-term patency with surgical bypass when the patient is fit and suitable vein is available ESC 2017. ESC 2017 recommends an endovascular-first strategy for femoropopliteal lesions shorter than 25 cm; for lesions 25 cm or longer, surgical bypass is preferred when the patient is not at high surgical risk, autologous vein is available, and life expectancy is reasonable. In CLTI, patients with an adequate single-segment great saphenous vein benefit from a bypass-first strategy, which reduces major adverse limb events and death compared with an endovascular-first approach BEST-CLI · 2022. When adequate vein is absent, treatment modality is tailored to patient risk and target anatomy without a demonstrated superiority for bypass. Single-segment great saphenous vein is the preferred conduit for all femoropopliteal bypass. In randomized trials, 5-year primary patency of above-knee femoropopliteal bypass is roughly 74% with saphenous vein versus 39% with PTFE, and prosthetic conduit performs worst below the knee, so prosthetic bypass is reserved for above-knee targets when no adequate vein is available GVG 2019 · Klinkert 2004.

The stepwise decision logic for severe femoropopliteal occlusive disease is:

1. Intervention is considered only after confirmed inadequate response to medical therapy and structured exercise for claudication, or following objective documentation of peripheral artery disease with CLTI signs.
2. Limb threat is graded using WIfI, and anatomic complexity is staged using GLASS for CLTI.
3. Preprocedural vein-conduit imaging determines single-segment great saphenous vein adequacy.
4. Endovascular therapy is the preferred initial approach for short lesions and infrapopliteal targets. When adequate single-segment great saphenous vein is lacking, modality is tailored to patient risk and target anatomy, without demonstrated superiority for bypass.
5. Bypass is favored for longer lesions or CLTI when adequate single-segment great saphenous vein is present and the patient is an operative candidate.

An unsalvageable limb or a non-ambulatory patient with limited life expectancy may warrant primary amputation or palliation rather than revascularization (detailed in the amputation chapter) GVG 2019.

Post-revascularization surveillance evaluates sustained functional benefit in claudication and limb salvage status in CLTI. Outcome measures, including primary patency, target-lesion revascularization, major adverse limb events, and amputation-free survival, follow standardized endpoint reporting guidelines SVS Reporting Standards 2016.

37.4Endovascular device selection

Device selection is tailored to lesion complexity and intended failure mode. Drug-coated balloon angioplasty and paclitaxel-eluting stents demonstrate durable antiproliferative benefit over standard balloon angioplasty in superficial femoral and popliteal disease Zilver PTX 2016 · LEVANT 2 2015 · IN.PACT SFA 2015. For mechanically demanding zones, such as the distal superficial femoral and proximal popliteal segments, interwoven nitinol stents provide high patency with mechanical fracture resistance SUPERB · 2015. Adjunctive devices, including rotational atherectomy and embolic protection systems, are used for complex or heavily calcified infrainguinal lesions, though atherectomy patency declines predictably over long-term follow-up Jetstream Atherectomy · 2026 · FCAT Series 2026.

37.5Areas of controversy

A late mortality signal was initially reported following the use of paclitaxel-coated balloons and stents in the femoropopliteal segment. A 2018 meta-analysis demonstrated higher crude all-cause death up to 5 years (14.7% vs 8.1%; RR 1.93, 95% CI 1.27 to 2.93) Katsanos 2018. An updated meta-analysis incorporating 15 randomized controlled trials and 5,859 patients subsequently found no significant increase in all-cause mortality or major amputation at 1, 2, or 5 years, while confirming that target-lesion-revascularization benefits attenuate by 5 years Updated Paclitaxel Meta-analysis 2026. Device selection remains individualized, with long-term surveillance required due to diminishing efficacy.

The definitive ranking of devices by territory remains unsettled. Single-center and real-world cohorts indicate varying restenosis rates and scoring-balloon performance across iliac, superficial femoral, and popliteal segments, but definitive standard-of-care superiority requires further randomized evaluation Territory EVT Cohort 2026 · Scoring Balloon Series 2026.